NEW YORK ─ Point-of-care diagnostic firm NanoDx and semiconductor manufacturer SkyWater Technology on Wednesday announced a technology transfer agreement for the qualification and production of nanoscale sensors used in rapid testing for numerous medical indications including COVID-19, traumatic brain injury, sepsis, and stroke.
NanoDx plans to pursue a US Food and Drug Administration Emergency Use Authorization for a rapid point-of-care COVID-19 test and is partnering with Bloomington, Minnesota-based SkyWater to ramp up to high-volume production of the product, the firms said.
Financial and other terms of the agreement were not disclosed.
Southborough, Massachusetts-based NanoDx is developing a point-of-care diagnostics platform that uses nanosensor technology to detect and quantify biomarkers in less than two minutes. The platform includes an array of ultrasensitive nanowires to detect and measure the biomarkers and associated infections in the bloodstream or other fluid specimens.
In July, NanoDx announced a licensing agreement to enable the integration of IBM Research's complementary metal-oxide-semiconductor technology with NanoDx’s nanosensor platform.